Angio News and Research RSS Feed - Angio News and Research

MESA, Curagita join forces to bring Diagnostic Imaging services to Germany

MESA, Curagita join forces to bring Diagnostic Imaging services to Germany

Medical Equipment Solutions and Applications, Europe's leader in multi-vendor service for Diagnostic Imaging systems, equipment and parts, and Heidelberg-based radiology management company Curagita are joining forces to bring new and broader solutions for a full range of Diagnostic Imaging services to the German healthcare market. [More]
Barnes-Jewish Hospital first to use VISIUS iMRI for over 1,000 procedures

Barnes-Jewish Hospital first to use VISIUS iMRI for over 1,000 procedures

IMRIS Inc. ("IMRIS" or the "Company") today announced that Barnes-Jewish Hospital in St. Louis is the first U.S. hospital to use VISIUS® iMRI for more than 1,000 procedures. [More]
FDA approves IMRIS’ VISIUS Surgical Theatre that integrates high-field MR scanners

FDA approves IMRIS’ VISIUS Surgical Theatre that integrates high-field MR scanners

IMRIS Inc. today announced US Food and Drug Administration clearance of the newest generation VISIUS® Surgical Theatre which integrates Siemens' latest high-field MR scanners. [More]
Zale Lipshy University Hospital receives 2013 Press Ganey Beacon of Excellence Award

Zale Lipshy University Hospital receives 2013 Press Ganey Beacon of Excellence Award

Zale Lipshy University Hospital at UT Southwestern Medical Center received the 2013 Press Ganey Beacon of Excellence Award for patient satisfaction, one of only three academic medical centers in the nation and one of 26 health care facilities selected nationally to receive that distinction. [More]
White paper addresses needs, challenges and solutions for improving mCRC treatment

White paper addresses needs, challenges and solutions for improving mCRC treatment

The Angiogenesis Foundation released a white paper at the 2013 European Cancer Congress that addresses the needs, challenges, and proposed solutions for improving treatment of metastatic colorectal cancer, the third most common cancer among men and the second most common among women worldwide. [More]
Study refocuses on how neuroblastoma tumors evolve in response to medicine and other factors

Study refocuses on how neuroblastoma tumors evolve in response to medicine and other factors

An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations—mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors. [More]
Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical

Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical

Regenerative medicine is a new, exciting field that is based upon the belief that the human body has the inherent power to heal itself, but in some instances it just needs a little help. [More]
Researchers discover two gene variants that raise risk of pediatric cancer neuroblastoma

Researchers discover two gene variants that raise risk of pediatric cancer neuroblastoma

Researchers have discovered two gene variants that raise the risk of the pediatric cancer neuroblastoma. Using automated technology to perform genome-wide association studies on DNA from thousands of subjects, the study broadens understanding of how gene changes may make a child susceptible to this early childhood cancer, as well as causing a tumor to progress. [More]
Kensey Nash to resolve Angio-Seal license disputes with St. Jude Medical

Kensey Nash to resolve Angio-Seal license disputes with St. Jude Medical

Kensey Nash Corporation today announced that the Company has entered into a settlement agreement with St. Jude Medical which resolves all disputes between the two companies relating to the Angio-Seal vascular closure device licenses, as well as other related claims. [More]
IMRIS unveils VISIUS Surgical Theatre

IMRIS unveils VISIUS Surgical Theatre

IMRIS Inc. today officially launched VISIUS Surgical Theatre, its new global product branding at the Congress of Neurological Surgeons (CNS) being held in Washington DC. [More]
Kensey Nash fourth quarter total revenues decrease 14% to $18.7 million

Kensey Nash fourth quarter total revenues decrease 14% to $18.7 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its fourth quarter and fiscal year ended June 30, 2011. [More]
Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI). [More]
Kensey Nash revenues decrease 7% to $18.6 million for third quarter fiscal 2011

Kensey Nash revenues decrease 7% to $18.6 million for third quarter fiscal 2011

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its third quarter ended March 31, 2011. [More]
Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease. [More]
Study finds reduction in pain favoring Mynx Vascular Closure Device to Angio-Seal Evolution Device

Study finds reduction in pain favoring Mynx Vascular Closure Device to Angio-Seal Evolution Device

AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint. [More]
Story of the heart: Literally as well as metaphorically

Story of the heart: Literally as well as metaphorically

Stephen Amidon, a novelist and co-author of The Sublime Engine: A Biography of the Human Heart, writes about the story of the human heart through the world of science, history, culture and our bodies with his brother Thomas who is a practicing cardiologist in Montana and a former medical director of The Hope Heart Institute. Thomas said, “Ironically, I did an angiogram on a patient last week who had very calcified and hardened arteries that were almost precisely in the shape of the Valentine heart… But I don't think the early depicters of that heart shape had access to the same view of the heart that I have.” [More]
Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Avantra Biosciences today announced the selection of TGen Drug Development as a key test site for Avantra's new biomarker quantitation platform. [More]
Avantra begins shipment of new Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay

Avantra begins shipment of new Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay

Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx™ BioChip Immunoassay. [More]
LMO1 gene variation can increase neuroblastoma risk

LMO1 gene variation can increase neuroblastoma risk

Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. The study team, led by researchers at The Children's Hospital of Philadelphia, found that common variants in the LMO1 gene increase the risk of developing an aggressive form of neuroblastoma, and also mark the gene for continuing to drive the cancer's progression once it forms. [More]
Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010. [More]